TECX Tectonic Therapeutic Inc.
Price (delayed)
$17.89
Market cap
$333.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.83
Enterprise value
$195.35M
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
Highlights
The EPS has surged by 80% year-on-year and by 48% since the previous quarter
Tectonic Therapeutic's quick ratio has increased by 33% from the previous quarter
TECX's debt has dropped by 91% year-on-year but it is up by 11% since the previous quarter
TECX's net income is down by 35% year-on-year and by 29% since the previous quarter
Tectonic Therapeutic's equity has decreased by 6% from the previous quarter
Key stats
What are the main financial stats of TECX
Market
Valuations
Earnings
Shares outstanding
18.66M
Market cap
$333.88M
Enterprise value
$195.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$58.02M
Net income
-$57.98M
EBIT
-$57.88M
EBITDA
-$55.8M
Free cash flow
-$59.24M
Per share
Balance sheet
Liquidity
EPS
-$6.83
EPS diluted
-$6.83
Free cash flow per share
-$6.98
Book value per share
$9.54
Revenue per share
$0
TBVPS
$18.01
Total assets
$152.91M
Total liabilities
$12.13M
Debt
$3.3M
Equity
$140.78M
Working capital
$135.25M
Debt to equity
0.02
Current ratio
12.65
Quick ratio
12.22
Net debt/EBITDA
2.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.2%
Return on equity
-42.5%
Return on invested capital
N/A
Return on capital employed
-41%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TECX stock price
How has the Tectonic Therapeutic stock price performed over time
Intraday
6.24%
1 week
-5.89%
1 month
-29.23%
1 year
16.47%
YTD
-61.25%
QTD
1.02%
Financial performance
How have Tectonic Therapeutic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.02M
Net income
-$57.98M
Gross margin
N/A
Net margin
N/A
TECX's net income is down by 35% year-on-year and by 29% since the previous quarter
TECX's operating income is down by 30% year-on-year and by 20% since the previous quarter
Growth
What is Tectonic Therapeutic's growth rate over time
Valuation
What is Tectonic Therapeutic stock price valuation
P/E
N/A
P/B
1.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 80% year-on-year and by 48% since the previous quarter
TECX's price to book (P/B) is 26% more than its 5-year quarterly average of 1.4 but 20% less than its last 4 quarters average of 2.2
Tectonic Therapeutic's equity has decreased by 6% from the previous quarter
Efficiency
How efficient is Tectonic Therapeutic business performance
Tectonic Therapeutic's ROE has soared by 52% YoY and by 24% from the previous quarter
The return on assets has increased by 18% year-on-year but it has declined by 4.7% since the previous quarter
Dividends
What is TECX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TECX.
Financial health
How did Tectonic Therapeutic financials performed over time
The total liabilities has shrunk by 72% YoY and by 34% QoQ
TECX's current ratio is up by 35% QoQ
TECX's debt is 98% smaller than its equity
The debt to equity has soared by 105% YoY
TECX's debt has dropped by 91% year-on-year but it is up by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.